41 completed. 41 Phase 2, 7 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 41 | Completed 41 |
| Phase 3 | 7 | Completed 7 |
| Phase 1 | 3 | Completed 3 |
Follow Vaginitis: new trials by email Literature Review of Vaginitis trials Research Report on Vaginitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Postbiotic as Adjunct Treatment for Vaginal Candidiasis Postbiotic, Placebo - Vaginal Candidiasis | Phase 2 / Phase 3 | Completed | Min-Tze LIONG | 99 | 2024-06-02 | 2026-07-07 |
| Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs Menstrual Cup - Bacterial Vaginosis, Vaginal Microbiome | Phase 2 | Completed | Rush University Medical Center | 408 | 2023-02-13 | 2026-08-24 |
| Live Double Combined Lactobacillus Capsule for Vaginal Use(IIb) Vaginal Lactobacillus Dual Probiotic Capsules, Placebo - Bacterial Vaginosis | Phase 2 | Completed | Guangdong Longchuangji Pharmaceutical Co., Ltd. | 66 | 2023-01-03 | 2026-02-18 |
| Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study Secnidazole 2 GM Oral Granules - Recurrent Bacterial Vaginosis | Phase 2 / Phase 3 | Completed | Indiana University | 24 | 2021-07-09 | 2024-02-05 |
| Live Double Combined Lactobacillus Capsule for Vaginal Use（IIa） Live double combined lactobacillus capsule for vaginal use（1*10^7CFU/capsule）+Metronidazole placebo, Low-dose group: Live double combined lactobacillus capsule placebo+Metronidazole, Live double combined lactobacillus capsule for vaginal use（1*10^8CFU/capsule）+Metronidazole placebo - Bacterial Vaginosis (BV) | Phase 2 | Completed | Guangdong Longchuangji Pharmaceutical Co., Ltd. | 57 | 2021-05-18 | 2026-02-18 |
| Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition LACTIN-V, Placebo - Bacterial Vaginosis, HIV Infections | Phase 2 | Completed | University of California, San Francisco | 45 | 2021-05-10 | 2024-08-13 |
| Suppression Of Bacterial Vaginosis (BV) [SUBVert] Placebo, TOL-463 - Bacterial Vaginosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 81 | 2019-09-09 | 2023-02-22 |
| The Effect of Probiotics on Maintenance of Health in Pregnancy and Infants Probiotic, Placebo - Pregnancy | Phase 2 | Completed | Lallemand Health Solutions | 180 | 2017-10-23 | 2023-02-02 |
| Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin Amoxicillin, Placebo - Vaginitis Gardnerella | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 97 | 2017-09-11 | 2020-08-28 |
| Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Fluconazole, SCY-078 - Candida Vulvovaginitis | Phase 2 | Completed | Scynexis, Inc. | 186 | 2017-08-01 | 2021-08-12 |
| ProF-001_Phase IIa Candiplus, Clotrimazole - Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Completed | ProFem GmbH | 84 | 2017-04-04 | 2019-03-14 |
| Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Oral Encochleated Amphotericin B (CAMB), Fluconazole - Vulvovaginitis, Yeast Infection | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 137 | 2016-11-01 | 2018-11-02 |
| TOL-463 Phase 2 Study for Vaginitis TOL-463 - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 2 | Completed | Toltec Pharmaceuticals, LLC | 106 | 2016-07-15 | 2018-03-09 |
| RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%) - Candidiasis, Vulvovaginal, Mycoses | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 126 | 2016-06-08 | 2020-08-31 |
| LACTIN-V Study for Recurrent Bacterial Vaginosis Lactobacillus crispatus CTV-05, Metronidazole, Placebo - Bacterial Vaginosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 228 | 2016-06-03 | 2020-03-04 |
| Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis 5% Monolaurin Vaginal Gel, Placebo - Bacterial Vaginosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 109 | 2016-04-14 | 2018-12-28 |
| Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis SCY-078, Fluconazole - Vulvovaginal Candidiasis | Phase 2 | Completed | Scynexis, Inc. | 96 | 2015-11-01 | 2019-07-12 |
| A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) VT-1161, Placebo - Recurrent Vulvovaginal Candidiasis | Phase 2 | Completed | Viamet | 254 | 2015-02-10 | 2019-10-15 |
| Probiotic Implementation as Help in Solving Vaginal Infections Lactobacillus rhamnosus BMX 54 - Vaginal Infection, ASC-US | Phase 2 | Completed | University of Roma La Sapienza | 117 | 2015-02-01 | 2017-12-13 |
| Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of AV and DIV IZN-6NVS Cream - Atrophic Vaginitis | Phase 1 / Phase 2 | Completed | Izun Pharma Ltd | 50 | 2014-12-01 | 2018-03-14 |
Showing 20 of 41. Sign in to see all of them.
Vaginosis, Bacterial (22) · Candidiasis, Vulvovaginal (14) · Trichomonas Vaginitis (4) · Vaginal Diseases (4) · Candidiasis (3) · HIV Infections (3) · Sexually Transmitted Diseases (3) · Atrophic Vaginitis (2) · Syphilis (2) · Trichomonas Infections (2) · Atypical Squamous Cells of the Cervix (1) · Birth Weight (1) · Chorioamnionitis (1) · Gonorrhea (1)
Female Urogenital Diseases (41) · Female Urogenital Diseases and Pregnancy Complications (41) · Genital Diseases (41) · Genital Diseases, Female (41) · Urogenital Diseases (41) · Vaginal Diseases (37) · Bacterial Infections and Mycoses (36) · Infections (36) · Bacterial Infections (24) · Vulvar Diseases (14) · Vulvitis (14) · Mycoses (13) · Vulvovaginitis (13) · Candidiasis (11)
Fluconazole (5) · Metronidazole (5) · TOL-463 (2) · VT-1161 (2) · ibrexafungerp (2) · Amoxicillin (1) · Benchmarking (1) · Clotrimazole (1) · Imiquimod (1) · Menstrual Hygiene Products (1) · Miconazole (1) · Nonoxynol (1) · Probiotics (1) · boric acid (1) · hydroxyethylcellulose (1)
National Institute of Allergy and Infectious Diseases (NIAID) (5) · Guangdong Longchuangji Pharmaceutical Co., Ltd. (2) · Population Council (2) · Scynexis, Inc. (2) · Starpharma Pty Ltd (2) · Viamet (2) · Assiut University (1) · CONRAD (1) · Centers for Disease Control and Prevention (1) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Ferrer Internacional S.A. (1) · Graceway Pharmaceuticals, LLC (1) · Indiana University (1) · Izun Pharma Ltd (1) · Karolinska Institutet (1)
United States (25) · Canada (2) · China (2) · Kenya (2) · South Africa (2) · Austria (1) · Dominican Republic (1) · India (1) · Israel (1) · Malaysia (1) · Spain (1) · Sweden (1) · Tanzania (1) · Thailand (1)
David Angulo, MD (2) · Alena Jandourek, MD (1) · Andrea R Thurman, MD (1) · Anke Hemmerling, MD, MPH, PhD (1) · Anne Macek, MD (1) · Charlotte E. Ellertson, MPA, Ph.D. (1) · Chemen Neal, MD (1) · Craig R Cohen, MD MPH (1) · Craig R Cohen, MD, MPH (1) · Douglas Kling (1) · Gabe Nussbaum, MD, PhD (1) · Gregory Reid, MSc, MBA (1) · Helena Kopp Kallner, MD, PhD (1) · Herbert Kiss, Ao.Univ.Prof.Dr. (1) · Jacques Kadoch, MD (1)
PMID 36396498, PMID 20644497, PMID 21992977, PMID 24983350, PMID 25935783, PMID 26210791, PMID 28697102, PMID 29304768, PMID 29474292, PMID 29534874, PMID 29697768, PMID 30184181, PMID 30807423, PMID 32402161, PMID 32818963, PMID 33207004, PMID 34555149, PMID 35113809, PMID 39516733, PMID 40194532, PMID 40206350, PMID 40970688, PMID 42326018, PMID 42678149
2009 (1), R01AI045468 (1), R01AI170564 (1), R01HD098978 (1)